Venture Portfolio - PhysioAssist


Key Figures

  • 2012
    Creation Date
  • 15
    Number of Employees
  • 2017
    Investment Date
  • Mérieux Participations 2
    Fund Name

Company Presentation

PhysioAssist has developed a unique expertise in bronchial mucus analysis and clearance. Their model of digital simulation allowed for a detailed analysis of the impact of vibrational signals on human mucus in the distant airways of the bronchi. The stagnation of mucus in these areas is often considered to be a root cause of pulmonary infections. Patients with obstructive pathologies have to clear their airways on a daily basis.

PhysioAssist’s lead product, Simeox™, delivers a simple solution to clear airways efficiently, particularly suited for COPD and Cystic Fibrosis patients. It is currently commercialized in France and some countries within Western Europe.

A session of treatment with Simeox™ typically lasts for 10 to 20 minutes and is supervised by a healthcare professional, and can be provided at home, to improve quality of life and patient compliance.


31 Parc du Golf - CS 90519 - 13593 Aix en Provence - FRANCE

Key Contacts